Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry.

Structure (London, England : 1993) - 5 Sept 2017

Lu Jia, Harrison Rane A, Li Lianbo, Zeng Mei, Gondi Sudershan, Scott David, Gray Nathanael S, Engen John R, Westover Kenneth D

Abstract excerpt

KRAS G12C, the most common RAS mutation found in non-small-cell lung cancer, has been the subject of multiple recent covalent small-molecule inhibitor campaigns including efforts directed at the guanine nucleotide pocket and separate work focused on an inducible pocket adjacent to the switch motifs. Multiple conformations of switch II have been observed, suggesting that switch II pocket (SIIP) binders may be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Crystallography, X-Ray
Share to Deuterium Exchange Measurement

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Design

Share to Enzyme Inhibitors

Share to Mass Spectrometry

Share to Molecular Conformation

Share to Proto-Oncogene Proteins p21(ras)

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 28781083
DOI: 10.1016/j.str.2017.07.003
PMCID: PMC8475952

Genes

KRAS
HDX

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry.PMID 28781083Read ↗

KRAS is vulnerable to reversible switch-II pocket engagement in cells.Semantic proximity Read ↗

Systematic cysteine scanning identifies a druggable pocket in oncogenic KRAS.Semantic proximity Read ↗

In Silico Evaluation of the Thr58-Associated Conserved Water with KRAS Switch-II Pocket Binders.Semantic proximity Read ↗

Beyond KRAS(G12C): Biochemical and Computational Characterization of Sotorasib and Adagrasib Binding Specificity and the Critical Role of H95 and Y96.Semantic proximity Read ↗

Biophysical and structural analysis of KRAS switch-II pocket inhibitors reveals allele-specific binding constraints.Semantic proximity Read ↗

A novel Imidazo[1,2-a]pyridine derivative modulates active KRASG12D through off-like conformational shifts in switch-I and switch-II regions, mimicking inactive KRASG12D.Semantic proximity Read ↗

Pharmacophoric analogs of sotorasib-entrapped KRAS G12C in its inactive GDP-bound conformation: covalent docking and molecular dynamics investigations.Semantic proximity Read ↗

Remodeling KRAS.Semantic proximity Read ↗

Defining An Expanded RAS Conformational Landscape Based on Over 700 Experimentally Determined Structures of KRAS, NRAS, and HRASSemantic proximity Read ↗

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRASG12C Inhibitor.Semantic proximity Read ↗

RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric siteSemantic proximity Read ↗

Ras Binder Induces a Modified Switch-II Pocket in GTP and GDP States.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.